|
 |
| home > epc > winter 2001 > a competitive analysis of the japanese pharmaceutical and biotechnology industries |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor
|
At the time of writing, Taisho Pharmaceutical Co Ltd and Tanabe Seiyaku Co Ltd have announced a merger under the tentative name of Taisho Tanabe Pharma Group. Both companies were in the top tier of Japanese pharmaceutical companies, with sales of 274 billion yen and 194 billion yen respectively, for the financial year end of March 2001. The question that now arises from the rhetoric of the Japanese pharmaceutical market is: does the merger mark the new beginning of the long awaited consolidation of the Japanese market? Or, is this a one-off event within the industry and what prospects exist for other Japanese pharmaceutical companies?
Japan is always described in any pharmaceutical journal as being the second largest pharmaceutical market in the world. Combine this with the prospect of a population of 127 million people, a drug expenditure of £355 per head, and the fastest ageing population in the world, and you have a market that is ripe for picking.
So why is there such a limited presence of foreign pharmaceutical companies in the marketplace and why are Japanese pharmaceutical companies so worried about their future prospects?
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
Clinical Trials in Latin America
9-10 September 2010, Lima, Peru
CBI’s Conference on Clinical Trials in Latin America, being held 9–10th September 2010 in Lima, Peru brings together key stakeholders involved with clinical trials in Latin America. Latin America is an increasingly desirable location for running clinical trials, and it is important for those involved to collaborate with colleagues and industry counterparts regarding the challenges of developing, executing and completing clinical trials in Latin America. This is a unique opportunity for pharmaceutical executives in Latin America to hear from key regulatory officials, pharmaceutical leaders, CROs and sites on how all stakeholders in the clinical process can ultimately achieve desired results.
More info >> |
|
 |
News and Press Releases |
 |
ClinTec International
ClinTec International, a global Clinical Research Organisation (“CRO”) announces a financial and strategic partnership with Elephant Capital Plc., an AIM market listed private equity firm. With an investment of £8 Million GBP, Elephant has acquired a significant minority stake in ClinTec. Through this investment, Elephant has entered the attractive clinical research base, where ClinTec operates as a global provider of outsourcing solutions addressing the drug development lifecycle. Managing Partner of Elephant Capital LLP, Gaurav Burman, and Non-Executive Director of Elephant Capital Plc, James Hauslein, have also made personal co-investments in this transaction.
More info >> |
|
 |
